Cargando…

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma

BACKGROUND: Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studies have shown that immunohistochemistry (IHC)-based detection of cancer-related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, GuoQing, Wang, LiJun, Yang, HanJin, Han, XiaoYan, Zheng, GaoFeng, Zheng, WeiYan, Sun, Jie, Shi, JiMin, Wu, WenJun, Zhao, Yi, He, DongHua, Wang, Bo, Cai, Zhen, He, JingSong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446722/ https://www.ncbi.nlm.nih.gov/pubmed/28560070 http://dx.doi.org/10.1186/s40164-017-0076-3

Ejemplares similares

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis
por: Huang, Yan, et al.
Publicado: (2019)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

Camalexin Induces Apoptosis via the ROS-ER Stress-Mitochondrial Apoptosis Pathway in AML Cells
por: Yang, Yang, et al.
Publicado: (2018)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
por: He, Donghua, et al.
Publicado: (2021)

Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells
por: Wu, Wenjun, et al.
Publicado: (2018)

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis
por: Sun, Tong, et al.
Publicado: (2021)

Astrocytoma development following complete multiple myeloma remission in a 49-year-old patient: A case report
por: HAN, XIAOYAN, et al.
Publicado: (2013)

Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease
por: Yang, Yang, et al.
Publicado: (2019)

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells
por: Lin, Xuanru, et al.
Publicado: (2017)

MiR-320a induces diabetic nephropathy via inhibiting MafB
por: He, Mengying, et al.
Publicado: (2019)

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

Clinical Characteristics, Microbiology, and Risk Factors for Mortality of Pre-Engraftment and Post-Engraftment Bloodstream Infection in Hematopoietic Stem Cell Transplantation Recipients
por: Chen, Weihao, et al.
Publicado: (2022)

Correction for: MiR-320a induces diabetic nephropathy via inhibiting MafB
por: He, Mengying, et al.
Publicado: (2022)

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
por: Wang, Siyu, et al.
Publicado: (2017)

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
por: Herath, N I, et al.
Publicado: (2014)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

MafA and MafB Regulate Genes Critical to β-Cells in a Unique Temporal Manner
por: Artner, Isabella, et al.
Publicado: (2010)

Loss of MafA and MafB expression promotes islet inflammation
por: Singh, Tania, et al.
Publicado: (2019)

Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf
por: Xu, Yujia, et al.
Publicado: (2020)

PB1962: COMPARISON OF EXPRESSION OF NSD2, CYCLIN D1 AND C-MAF BY PLASMA CELLS IN BONE MARROW AND BONE PLASMACYTOMA IN PATIENTS WITH PLASMA CELL MYELOMA
por: Mamaeva, E., et al.
Publicado: (2022)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)
por: ZI, FUMING, et al.
Publicado: (2015)

MafA and MafB Regulate Pdx1 Transcription through the Area II Control Region in Pancreatic β Cells
por: Vanhoose, Amanda M., et al.
Publicado: (2008)

MafB Maintains β-Cell Identity under MafA-Deficient Conditions
por: Deng, Zhaobin, et al.
Publicado: (2022)

Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
por: Zhang, Mingming, et al.
Publicado: (2016)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
por: Liu, Yang, et al.
Publicado: (2022)

The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3β in myeloma by atypical K63-linked polyubiquitination
por: Zhang, Zubin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2pkojeb19kgpmpkjftalrjvkv9